We are live on ! Find out more
RCUS icon

Arcus Biosciences

75 hedge funds and large institutions have $274M invested in Arcus Biosciences in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

17% more capital invested

Capital invested by funds: $235M → $274M (+$38.8M)

2.8% more ownership

Funds ownership: 56.29%59.1% (+2.8%)

0% more funds holding

Funds holding: 7575 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

Holders
75
Holders Change
Holders Change %
0%
% of All Funds
1.48%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
10
Increased
34
Reduced
15
Closed
10
Calls
$13K
Puts
Net Calls
+$13K
Net Calls Change
+$14K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
76
Wellington Management Group
Massachusetts
-$23.1M -2,541,117 Closed
OAM
77
Oxford Asset Management
United Kingdom
-$267K -29,320 Closed
Susquehanna International Group
78
Susquehanna International Group
Pennsylvania
-$184K -20,271 Closed
ARTA
79
A.R.T. Advisors
New York
-$167K -18,401 Closed
B
80
Bailard
California
-$121K -13,300 Closed
Acadian Asset Management
81
Acadian Asset Management
Massachusetts
-$70K -7,708 Closed
Victory Capital Management
82
Victory Capital Management
Texas
-$41K -4,491 Closed
TRCT
83
Tower Research Capital (TRC)
New York
-$10K -1,052 Closed
IUHSA
84
Itau Unibanco Holding S.A.
Brazil
-$4K -464 Closed
Simplex Trading
85
Simplex Trading
Illinois
-$479 -57 Closed

RCUS Hedge Fund Activity: Q4 2019 in Review

75 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2019, worth a combined $274M — up 17% from $235M a quarter earlier.

Fund positioning in RCUS was balanced in Q4 2019: 10 funds opened new positions, 10 closed out, 34 added to existing stakes and 15 trimmed.

The largest buyer was Boxer Capital, adding an estimated $11.5M. The largest seller was Wellington Management Group, exiting entirely with an estimated $23.1M sold.

  • 75 institutional investors held Arcus Biosciences (RCUS) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $274M of Arcus Biosciences stock for Q4 2019, up 17% quarter-over-quarter.
  • 10 funds opened new Arcus Biosciences positions in Q4 2019 and 10 closed out, a net change of 0 holders.
  • The largest Arcus Biosciences buyer in Q4 2019 was Boxer Capital, an estimated $11.5M added.
  • The largest Arcus Biosciences seller in Q4 2019 was Wellington Management Group, an estimated $23.1M sold.

Based on aggregated 13F filings for Q4 2019.